Amarin Corporation plc revised preliminary unaudited earnings guidance for the fourth quarter of 2015. For the fourth quarter the company expects net product revenue to be approximately $26.0 million, which is 8% over the upper range of Amarin's prior guidance.

For the full year 2015, the company expects net product revenue to be approximately $80.0 million.

For the full year 2016, the company expects total net product revenue (excluding licensing revenue) of between $105 and $120 million in 2016, which is expected to position Amarin to enter 2017 cash flow positive from commercial operations, excluding REDUCE-IT and other research and development (R&D) expenses not required to sustain current commercial operations. Revenue growth in 2016 is expected to remain variable from quarter to quarter. In particular, as experienced in each of the past two years, revenues in the first quarter of 2016 are expected to be impacted by seasonal factors such as the effect of new year insurance deductibles on consumer behavior regarding prescription refills, particularly for therapies treating asymptomatic, chronic conditions, such as Vascepa.